Our Pricing

Wegovy Private Prescription UK: Clinical Overview and Access

Published on: June 03, 2026

Securing a wegovy private prescription UK has become significantly more accessible through registered online pharmacies like Cured Pharmacy, where transparent pricing starts from £79.00 and includes a comprehensive clinical assessment by UK prescribers. Wegovy (semaglutide 2.4mg) represents the first once-weekly GLP-1 receptor agonist licensed by the MHRA specifically for chronic weight management in adults with obesity or overweight with weight-related comorbidities.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a naturally occurring hormone involved in appetite regulation and glucose metabolism [1]. When administered subcutaneously once weekly, semaglutide binds to GLP-1 receptors in the brain's appetite centres, reducing hunger signals and increasing feelings of fullness after meals. This mechanism helps patients consume fewer calories without the constant sensation of deprivation that undermines traditional calorie-restriction approaches.

The STEP 1 clinical trial demonstrated that adults using Wegovy alongside lifestyle interventions achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% in the placebo group [1]. Notably, 83.5% of participants on semaglutide 2.4mg lost at least 5% of their initial body weight, and 66.1% achieved at least 10% weight loss — outcomes rarely seen with behavioural interventions alone [1].

Beyond appetite suppression, semaglutide slows gastric emptying, which prolongs the sensation of satiety after eating and helps stabilise postprandial blood glucose levels [2]. This dual action on both central appetite pathways and peripheral digestive processes explains why patients often report sustained weight loss throughout the treatment course, provided they maintain the prescribed dosing schedule.

Wegovy Private Prescription UK: The Clinical Assessment Process

All Wegovy prescriptions in the UK require clinical assessment by a registered prescriber, whether obtained through the NHS or private services. At Cured Pharmacy, the online consultation typically takes under three minutes and covers your medical history, current medications, weight management goals, and any contraindications that might affect suitability for semaglutide therapy.

Our UK-registered clinical team, overseen by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), reviews every consultation to ensure Wegovy is clinically appropriate for your individual circumstances. The MHRA licensing criteria specify that Wegovy should be prescribed for adults with a body mass index (BMI) of 30 kg/m² or greater, or 27 kg/m² or greater in the presence of at least one weight-related comorbidity such as hypertension, type 2 diabetes, or dyslipidaemia [3].

If approved, your prescription is issued electronically and dispensed from our GPhC-registered pharmacy (9012511) with discreet packaging and tracked delivery. The entire process — from consultation to doorstep delivery — is designed to remove the traditional barriers of GP waiting times and pharmacy stock shortages that have frustrated many UK patients seeking weight management support.

What to Expect During Your Consultation

The clinical questionnaire covers essential safety screening questions: current weight and height, previous weight loss attempts, medications that may interact with semaglutide (particularly insulin or sulfonylureas), history of pancreatitis or medullary thyroid carcinoma, and whether you're pregnant or planning pregnancy. These questions aren't bureaucratic obstacles — they're critical safety checks that protect you from potentially serious adverse events. Semaglutide is contraindicated in pregnancy and in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [3].

Wegovy Dosing Schedule and Administration

Wegovy follows a structured dose-escalation protocol designed to minimise gastrointestinal side effects whilst optimising therapeutic efficacy. The standard titration schedule begins at 0.25mg once weekly for four weeks, then increases monthly through 0.5mg, 1mg, and 1.7mg doses before reaching the maintenance dose of 2.4mg weekly [3]. This gradual escalation allows your digestive system to adapt to semaglutide's effects on gastric emptying.

Each Wegovy pen is pre-filled and designed for single use, with a hidden needle that automatically retracts after injection. You'll inject subcutaneously into the abdomen, thigh, or upper arm on the same day each week, though the specific time of day doesn't matter. If you miss a dose and it's been less than five days, take it as soon as you remember; if more than five days have passed, skip that dose and resume your regular schedule [3].

Most patients remain on the 2.4mg maintenance dose indefinitely, as clinical trials show that weight regain typically occurs when semaglutide is discontinued [4]. This isn't a sign of treatment failure or lack of willpower — it reflects the biological reality that obesity involves persistent metabolic adaptations that GLP-1 agonists help counteract. Your prescriber will review your progress regularly to assess whether continuing treatment remains clinically beneficial.

Managing Common Side Effects

Nausea, diarrhoea, constipation, and abdominal discomfort are the most frequently reported side effects, particularly during dose escalation [1]. These symptoms are generally mild to moderate and diminish over time as your body adapts. Eating smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated can help manage gastrointestinal symptoms. If side effects become intolerable, your prescriber may recommend staying at your current dose for an additional week or two before escalating further.

Wegovy Price UK: Understanding Private Prescription Costs

Private Wegovy prescriptions in the UK vary significantly across pharmacies, with monthly costs reflecting both the medication itself and the clinical services provided. At Cured Pharmacy, Wegovy starts from £79.00 — a price that includes your clinical consultation, prescription issuance, and discreet delivery, with no hidden fees added at checkout. This transparent upfront pricing allows you to budget accurately for your weight management journey.

The cost per pen varies depending on your prescribed dose during the titration phase, with lower starter doses generally priced below the maintenance dose. Unlike some providers who advertise low entry prices but increase costs dramatically at higher doses, Cured Pharmacy maintains competitive pricing throughout your treatment course. We also guarantee the lowest prices in the UK — if you find genuine UK-licensed Wegovy cheaper elsewhere, we'll match it.

It's worth noting that NHS Wegovy prescriptions remain extremely limited due to NICE guidance restricting use to specialist weight management services, with an estimated two-year waiting list in many regions [5]. Private prescriptions offer immediate access for eligible patients who meet the clinical criteria, removing the uncertainty of waiting lists whilst maintaining the same rigorous safety standards through UK-registered prescribers and GPhC-regulated pharmacies.

Wegovy vs Saxenda: Comparing GLP-1 Weight Loss Treatments

Both Wegovy and Saxenda are MHRA-licensed GLP-1 receptor agonists for weight management, but they differ in active ingredient, dosing frequency, and clinical outcomes. Saxenda contains liraglutide, a shorter-acting GLP-1 analogue that requires daily subcutaneous injection, whilst Wegovy's semaglutide formulation allows once-weekly dosing due to its extended half-life [2][6].

Head-to-head trial data shows semaglutide produces greater weight loss than liraglutide at their respective licensed doses. The STEP 8 trial directly compared semaglutide 2.4mg weekly against liraglutide 3mg daily, finding that semaglutide resulted in 15.8% average weight loss versus 6.4% with liraglutide over 68 weeks [6]. This nearly 10-percentage-point difference reflects semaglutide's superior receptor binding affinity and longer duration of action.

Saxenda may suit patients who prefer daily injections for psychological reasons or those who've previously used liraglutide successfully for diabetes management. However, the weekly injection schedule of Wegovy significantly improves adherence for most patients, and the superior weight loss outcomes make it the first-line choice for many UK prescribers when both options are clinically appropriate.

Switching Between GLP-1 Treatments

If you're currently using Saxenda and considering switching to Wegovy, your prescriber will typically recommend stopping liraglutide and starting semaglutide at the initial 0.25mg dose rather than jumping directly to a higher dose. This approach minimises gastrointestinal side effects, even though you've already been exposed to GLP-1 agonist therapy. The pharmacokinetic differences between the two medications mean your body needs time to adjust to semaglutide's longer duration of action.

Who Should Not Use Wegovy

Wegovy is contraindicated in several important patient groups, and your prescriber will screen for these conditions during your clinical assessment. Absolute contraindications include personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, pregnancy or breastfeeding, and known hypersensitivity to semaglutide or any excipients in the formulation [3].

Patients with a history of pancreatitis require careful consideration, as GLP-1 receptor agonists have been associated with acute pancreatitis in post-marketing surveillance, though causality remains uncertain [3]. If you have severe gastroparesis or inflammatory bowel disease, semaglutide's effects on gastric emptying may exacerbate symptoms. Type 1 diabetes is not an approved indication for Wegovy, and patients using insulin or sulfonylureas require dose adjustments to prevent hypoglycaemia when starting semaglutide.

Age considerations matter too: Wegovy is not licensed for use in patients under 18 years in the UK, and elderly patients (over 75 years) have limited clinical trial data, though no specific dose adjustment is recommended based solely on age [3]. Your prescriber will weigh these factors alongside your individual medical history to determine whether Wegovy represents a safe and appropriate treatment option for your circumstances.

Drug Interactions to Discuss

Semaglutide's effect on gastric emptying can alter the absorption of oral medications, particularly those with narrow therapeutic windows like levothyroxine or warfarin. If you take oral contraceptives, be aware that delayed gastric emptying during the first weeks of Wegovy treatment may theoretically reduce contraceptive efficacy, though this hasn't been demonstrated in clinical trials [3]. Always inform your prescriber of all medications, supplements, and herbal products you're taking to identify potential interactions.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Knudsen, L. B., & Lau, J. (2019). The Discovery and Development of Liraglutide and Semaglutide. Frontiers in Endocrinology, 10, 155. https://doi.org/10.3389/fendo.2019.00155 [accessed 13 August 2026]
3. Novo Nordisk. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen: Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency. https://www.medicines.org.uk/emc/product/13799 [accessed 13 August 2026]
4. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
5. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity [TA875]. NICE. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
6. Rubino, D. M., et al. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA, 327(2), 138–150. https://doi.org/10.1001/jama.2021.23619 [accessed 13 August 2026]
7. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
8. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
9. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Weight loss results vary between individuals and depend on adherence to treatment and lifestyle modifications.